Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Product containing precisely cefradine 50 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
sølvsulfadiazin 10 mg/g creme |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely clofazimine 50 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
ciprofloxacinhydrochlorid 750 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
ciprofloxacin 10 g/100 ml suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
ciprofloxacinhydrochlorid 250 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
ciprofloxacinhydrochlorid 100 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
ciprofloxacinhydrochlorid 500 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
makrokrystallinsk nitrofurantoin 50 mg kapsel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely nitrofurantoin 5 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Tobramycin 3 mg/mL eye solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
azithromycindihydrat 1 g suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
azithromycindihydrat 1200 mg suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
azithromycindihydrat 600 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
azithromycindihydrat 250 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
azithromycindihydrat 100 mg/5 ml suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
cefpodoximproxetil 100 mg/5 ml suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
cefpodoximproxetil 50 mg/5 ml suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
cefpodoximproxetil 200 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Bacampicillin hydrochloride 400 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Tobramycin 3 mg/g eye ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Ciprofloxacin 2mg/mL |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Levofloxacin 25mg/mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Cefadroxil 1 g oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
tetracyclin 125 mg/5 ml syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
ceftazidim 2 g/100 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
ceftazidim 100 g/hætteglas pulver |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely ofloxacin 3 milligram/1 milliliter conventional release ear solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Ciprofloxacin 200mg solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Ciprofloxacin 400mg solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
ciprofloxacin 1200 mg opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
levofloxacin 5mg/ml oftalmisk opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
minocyclinhydrochlorid 100 mg pellet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
minocyclinhydrochlorid 50 mg pellet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
norfloxacin 0,3 % opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Demeclocycline hydrochloride 300 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
tetracyclinhydrochlorid 12,7 mg/enhed |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
tetracyclinhydrochlorid 1 % wt/vol suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
tetracyclinhydrochlorid 1 % salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
cefaclormonohydrat 187 mg/5 ml pulver til oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
cefaclormonohydrat 375 mg/5 ml pulver til oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
polymyxin B-sulfat 100 % pulver |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
co-amoxiclav 400 mg/57 mg/5 ml oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
bacitracinzink 500 enheder + polymyxin B-sulfat 10.000 enheder salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Benzoyl peroxide + clindamycin phosphate 50mg/10mg gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
benzoylperoxid 50 mg + erythromycin 30 mg gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
colistinsulfat + hydrocortisonacetat + neomycinsulfat 3 mg/10 mg/3,3 mg opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
dexamethason 1 mg + neomycinsulfat 3,5 mg salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
dexamethason 0,1 %wt/vol + tobramycin 0,3 %wt/vol suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
dexamethason 1 mg + tobramycin 3 mg salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
dexamethasonnatriumphosphat 1 mg +neomycinsulfat 3,5 mg opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
erythromycinethylsuccinat 200 mg + sulfisoxazolacetyl 600 mg oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely fluorometholone 1 milligram/1 milliliter and sulfacetamide sodium 100 milligram/1 milliliter conventional release eye suspension (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
gentamicinsulfat 0,3 % wt/wt + prednisolonacetat 0,6 % wt/wt salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
gentamicinsulfat + prednisolonacetat 0,3 %/1 % vol/vol suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
gramicidin 0,025 mg + neomycinsulfat 1,75 mg + polymyxin B-sulfat 10.000 enheder opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
hydrocortison + neomycinsulfat + polymyxin B-sulfat 10 mg/5 mg/1,6 mg suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
hydrocortison + neomycinsulfat + polymyxin B-sulfat 10 mg/5 mg/10.000 opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
hydrocortison 10 mg + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
hydrocortison + neomycinsulfat + polymyxin B-sulfat 10 mg/7,5 mg/10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
hydrocortison 10 mg + neomycinsulfat 7,5 mg + polymyxin B-sulfat 1.000 enheder opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
hydrocortison + polymyxin B 5 mg/10.000 enheder dråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
hydrocortisonacetat 5 mg + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder creme |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Isoniazid 150 mg and rifampicin 300 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely methenamine mandelate 500 milligram and monobasic sodium phosphate 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
neomycinsulfat + polymyxin B-sulfat + prednisolonacetat 0,35 %/10.000 enheder/0,5 % wt/vol suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely nitrofurantoin macrocrystal 25 milligram and nitrofurantoin monohydrate 75 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely oxytetracycline hydrochloride 250 milligram and phenazopyridine hydrochloride 50 milligram and sulfamethizole 250 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
benzylpenicillin, benzathin + benzylpenicillin, procain 300.000 enheder/300.000 enheder injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
phenylephrinhydrochlorid 1,25 mg + sulfacetamidnatrium 150 mg opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
polymyxin B-sulfat + trimethoprimsulfat 10.000 enheder/1 mg opløsning til oftalmisk anvendelse |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
prednisolonacetat + sulfacetamidnatrium 0,2 % wt/vol/10 % wt/vol suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Prednisolone acetate 2 mg/g and sulfacetamide sodium 100 mg/g eye ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
prednisolonacetat + sulfacetamidnatrium 0,25 % wt/vol/10 % wt/vol suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Prednisolone acetate 2.5 mg/g and sulfacetamide sodium 100 mg/g eye ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
prednisolonacetat 5 mg + sulfacetamidnatrium 100 mg salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
prednisolonacetat 5 mg + sulfacetamidnatrium 100 mg suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
prednisolonnatriumphosphat 2,5 mg + sulfacetamidnatrium 100 mg opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
sulfabenzamid 184 mg + sulfacetamid 143,75 mg + sulfathiazol 172,5 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Sulfabenzamide + sulfacetamide + sulfathiazole 3.7%ww/2.86%ww/3.42%ww cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
sulfamethoxazol + trimethoprim 200 mg/40 mg suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
sulfamethoxazol + trimethoprim tablet a 400 mg/80 mg |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
sulfamethoxazol + trimethoprim tablet a 800 mg/160 mg |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing ertapenem (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
ertapenem 1 g pulver til infusionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing sulfanilamide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Cleocin t 10mg/ml lotion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
sulfasalazin tablet med modificeret udløsning 500 mg |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
amikacin 500 mg/100 ml infusionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
amikacin 62,5 mg/ml injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
gentamicin 70 mg/100 ml infusionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
gentamicin 90 mg/100 ml infusionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
gentamicinsulfat 40 mg/100 ml injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
isoton gentamicinsulfat 40 mg/100 ml injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
gentamicinsulfat 0,8 mg/ml injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
isoton gentamicinsulfat 0,8 mg/ml injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
gentamicinsulfat 1,2 mg/ml injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
isoton gentamicinsulfat 1,2 mg/ml injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|